News | November 02, 2025
Dr Lal Path Labs reports consolidated Q2 FY26 PAT at Rs. 150.6 Cr
The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025
The company has posted net profit of Rs. 283 crore for the 6 months period ended September 30, 2025
Dabur India has reported total income of Rs. 3,331.45 crore during the period ended September 30, 2025
Tatva Chintan Pharma Chem has reported total income of Rs. 124.52 crore during the period ended September 30, 2025
Dr Reddys Laboratories has reported total income of Rs. 8,805.1 crore during the period ended September 30, 2025
Revenues up 13.1% year-over-year; Continued momentum driven by organic growth, strategic partnerships, and acquisitions
Long-term OGSIVEO treatment for up to four years associated with further tumor reductions, increased objective response rate, sustained symptom improvement, and consistent safety profile
TTK Healthcare has reported total income of Rs. 222.58 crore during the period ended September 30, 2025
Investigational cell therapy bemdaneprocel continues to demonstrate a favorable safety profile at 36 months in Phase I trial participants
The Phase Ib MAD study is a randomized, double-blind, placebo-controlled trial conducted in the United States
Free cash flow also reached €63 million, representing an 11 percent increase compared to the high benchmark set in 2024
Subscribe To Our Newsletter & Stay Updated
